Study title: Acta Psychiatr Scand. 2004 Feb;109(2):140-6. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Serra-Mestres J, Ring HA, Costa DC, Gacinovic S, Walker Z, Lees AJ, Robertson MM, Trimble MR.Acta Psychiatr Scand. 2004 Feb;109(2):140-6. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Serra-Mestres J, Ring HA, Costa DC, Gacinovic S, Walker Z, Lees AJ, Robertson MM, Trimble MR.
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Nervous System Diseases | |||||
| Brands: | |||||
| MAH holders: | |||||
| Assessment: | |||||
| Active substance: Gentian (root | |||||
| ATC code: V09A B 03 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |